Skip to content
Screener

Total Cost of Revenue at other companies

Danaher logo
DanaherDHR
$2.65B+10.0%
Repligen logo
RepligenRGEN
$94.09M+3.1%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$282.7M+1.2%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$1.72M-68.0%
Revvity logo
RevvityRVTY
$323.46M+11.8%
Agilent Technologies logo
Agilent TechnologiesA
$845M+5.4%

Segments

By segment

See full
TriLink$18.32M
Cygnus$2.82M

By product

See full
Shipping and Handling$4.3M+4.9%

Other financials

Income statement

See full
Revenue$51.4M+8.5%
Gross profit$20.7M+166%
Operating income-$15.1M+77.2%
Net income-$12.4M+68.6%
EPS (diluted)-$0.08+70.4%

Balance sheet

See full
Cash & equivalents$70.6M-73.8%
Total debt$176.7M-52.4%
Total equity$204.6M-23.0%
Total assets$603.7M-32.7%

Cash flow

See full
Operating cash flow$4.0M+139%
CapEx$370.0K-87.1%
Free cash flow$3.6M+128%

Valuation

See full
Market cap$918.96M+210%
Enterprise value$1.03B+158%
P/S4.4×+3.1×

Profitability

See full
Gross margin34.9%+4.4pp
Operating margin-56.1%-21.3pp
Net margin-37.1%-13.6pp
FCF margin-17.2%

Returns & leverage

See full
Return on equity-32.9%-9.4pp
Debt / equity0.9×-0.5×
Current ratio4.1×-1.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001823239-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$51,442$47,397$117,279$94,247
Cost of revenue30,79239,62962,92878,754
Gross profit20,6507,76854,35115,493
Operating expenses:
Selling, general and administrative32,07038,71561,16278,279
Research and development3,7024,8827,5919,770
Goodwill impairment30,44942,884
Restructuring(33)2,845

Item 1. Financial Statements

FAQ

What is Maravai LifeSciences Holdings, Inc.'s total cost of revenue?
Maravai LifeSciences Holdings, Inc. (MRVI) reported total cost of revenue of $30.79M in Q2 2026.
How has Maravai LifeSciences Holdings, Inc.'s total cost of revenue changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s total cost of revenue decreased by 22.3% year-over-year, from $39.63M to $30.79M.
What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s total cost of revenue?
Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s total cost of revenue has grown at a 1.9% compound annual growth rate (CAGR), from $140.56M to $151.75M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Maravai LifeSciences Holdings, Inc.'s total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude